Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  afatinib dimaleate
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Status: Active
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: 1200.209, NCI-2016-00277, NCT02514174
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Afatinib Dimaleate and Trastuzumab in Treating Patients with Refractory Metastatic Esophagus or Stomach Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-166, NCI-2012-00414, NCT01522768
Afatinib Dimaleate, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-464, NCI-2012-01535, 1200.158, NCT01553942
Afatinib Dimaleate in Treating Patients with Stage I-III Non-small Cell Lung Cancer That Was Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-504, NCI-2013-01108, NCT01746251
Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-0540/ 1200.171, NCI-2014-00859, 13-0540, NCT02122172
Afatinib Dimaleate in Treating Patients with Stage IA-IIIA Non-small Cell Lung Cancer before Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0305, NCI-2015-00357, NCT02271906
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, EAY131-A, EAY131-B, EAY131-E, EAY131-F, EAY131-G, EAY131-H, EAY131-I, EAY131-N, EAY131-P, EAY131-Q, EAY131-R, EAY131-S1, EAY131-S2, EAY131-T, EAY131-U, EAY131-V, EAY131-X, NCT02465060
Afatinib Dimaleate and Radiation Therapy with or without Docetaxel in Treating Patients with Head and Neck Cancer Previously Treated with Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-267, NCI-2013-00626, NCT01783587
Afatinib Dimaleate and Dasatinib in Treating Patients with Advanced or Recurrent Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17176, NCI-2014-00003, 1200.166, BI 1200.166, BMS CA180-379, CA180-379, NCT01999985
BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1280.16, NCI-2015-01371, NCT02191891
Pembrolizumab and Afatinib Dimaleate in Treating Patients with Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer with Resistance to Erlotinib Hydrochloride
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#250, NCI-2015-00126, UCDCC#250; 1200.237 (BIPI); 51657 (Merck), NCT02364609
Afatinib Dimaleate and Capecitabine in Treating Patients with Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 9078, NCI-2015-00684, NCT02451553
Start Over